How Significant Can Keytruda Be For Merck?

Merck has stated that its drug will cost roughly $12,500 per month for treatment and targets advanced melanoma that accounts for most of the deaths from skin cancer cases. This means that only patients suffering from advanced melanoma, and not in the initial stages, will be primary customers for Keytruda.